Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $206.67

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $206.67.

KRYS has been the topic of several research reports. Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Chardan Capital restated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several large investors have recently added to or reduced their stakes in KRYS. Bank of New York Mellon Corp grew its stake in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Krystal Biotech by 3.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,461 shares of the company’s stock valued at $819,000 after buying an additional 169 shares during the period. Principal Financial Group Inc. raised its position in shares of Krystal Biotech by 1,972.0% during the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after buying an additional 117,510 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $319,000. Finally, CIBC Asset Management Inc bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $250,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 1.2 %

Krystal Biotech stock opened at $158.33 on Wednesday. The stock has a market cap of $4.55 billion, a P/E ratio of 89.45 and a beta of 0.80. The stock has a 50 day moving average of $176.51 and a 200-day moving average of $183.98. Krystal Biotech has a 52 week low of $107.50 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the firm earned ($0.67) EPS. The company’s revenue was up 879.9% on a year-over-year basis. As a group, equities analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).